WAT stock forecast, quote, news & analysis
Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools... Show more
Waters Corporation (WAT) Stock Analysis: Integration Momentum Meets a Pivotal Q2 Earnings Test
Key Takeaways
- Waters Corporation shares have traded in a relatively tight range over the past 30 days, declining approximately 0.5% from $379.29 to $377.31, as investors await the company's Q2 2026 earnings report scheduled for August 4.
- The transformative $17.5 billion acquisition of BD's Biosciences and Diagnostic Solutions businesses, which closed in February 2026, has reshaped Waters into a diversified life sciences and diagnostics powerhouse with projected full-year revenue exceeding $6.4 billion.
- Q1 2026 results significantly exceeded expectations, with adjusted EPS of $2.70 beating consensus estimates by $0.39 and organic constant-currency revenue growing 11% year-over-year.
- Analyst sentiment remains constructive with a consensus "Buy" rating and an average price target of approximately $413, implying roughly 9.5% upside from recent levels.
- Institutional ownership stands at 94.01%, reflecting strong professional investor conviction in the company's post-acquisition trajectory.
Current Market Snapshot
Waters Corporation (WAT) shares closed at $377.31 on July 31, 2026, marking a modest 0.5% decline over the trailing 30-day period. The stock has navigated a volatile but range-bound pattern, touching an intra-period low of approximately $345 on July 21 before rebounding sharply to a high near $392 on July 29 — a swing of nearly 14% — only to settle back near the $377 level. This price action reflects a market in waiting mode, with traders positioning cautiously ahead of the company's Q2 earnings release on August 4, which will offer the second comprehensive look at the combined company's performance since the landmark BD transaction. Waters' 50-day moving average sits near $362, while its 200-day moving average is around $346, suggesting an upward medium-term trend despite near-term consolidation.
Waters Corporation (WAT) Business Overview and Competitive Position
Waters Corporation is a global leader in analytical instruments, laboratory software, and diagnostic technologies. Headquartered in Milford, Massachusetts, the company designs, manufactures, and services high-performance liquid chromatography (HPLC) and mass spectrometry (MS) systems, thermal analysis instruments, and a broad portfolio of consumables and informatics solutions. Its customers span pharmaceutical and biotechnology firms, contract research organizations, academic and government institutions, clinical diagnostics labs, and food and environmental testing facilities.
The company's competitive moat was dramatically expanded through the February 2026 acquisition of Becton Dickinson's Biosciences and Diagnostic Solutions businesses — a transaction that added flow cytometry, microbiology, and molecular diagnostics capabilities and roughly doubled Waters' revenue base. The combined entity now operates across four divisions: Analytical Sciences, Biosciences, Advanced Diagnostics, and Materials Sciences. With approximately 16,000 employees worldwide and a market capitalization of roughly $37 billion, Waters competes alongside peers such as TMO, DHR, and A in the life sciences tools and diagnostics space.
Recent Developments Driving WAT
The most consequential recent development remains the BD Biosciences and Diagnostic Solutions acquisition, which closed on February 9, 2026. The first quarter of 2026 — the inaugural reporting period reflecting the combined entity — delivered standout results. Total reported revenue reached $1.267 billion, with organic revenue growing 13% as reported and 11% in constant currency. Adjusted EPS of $2.70 represented 20% year-over-year growth and exceeded consensus estimates by $0.39. The acquired businesses contributed $520 million in revenue during the owned period, surpassing internal guidance by $40 million.
Management raised full-year 2026 guidance following the Q1 beat, projecting organic constant-currency revenue growth of 6.5% to 8.0%, total reported revenue of $6.405 billion to $6.455 billion, and adjusted EPS of $14.40 to $14.60. The integration is tracking ahead of schedule, with Waters targeting $55 million in cost synergies and $50 million in revenue synergies for 2026. Key regulatory milestones have also bolstered sentiment, including FDA 510(k) clearance for the BD Onclarity HPV self-collection kit and the BD BACTEC FXI Culture System for bloodstream infection detection.
Analyst activity has been notably bullish. Goldman Sachs raised its price target to $425 with a Buy rating in July, while Bernstein initiated coverage with an Outperform rating and a $435 target. RBC Capital launched coverage with an Outperform rating and a $435 target, and Barclays maintained its Buy rating with a $425 target. The consensus Moderate Buy rating is supported by 13 Strong Buy ratings, 3 Buy ratings, and 8 Hold ratings among 24 analysts, with no Sell recommendations.
Institutional investors have also demonstrated conviction. Allspring Global Investments increased its Waters stake by over 18,000% in Q1, acquiring 486,198 shares, while Principal Financial Group boosted its holdings by 17% to over 1 million shares. Bank of New York Mellon increased its position by 63.6%, adding more than 205,000 shares. Overall institutional ownership now stands at 94.01%.
Trending AI Robots
For traders seeking data-driven approaches to navigate stocks like Waters Corporation, Tickeron's Trending AI Robots page offers a curated view of top-performing AI-powered trading bots. Tickeron's platform hosts hundreds of AI trading bots that actively trade thousands of tickers across global markets, but only the most consistently relevant and highest-performing strategies earn placement in this featured section. These bots employ diverse methodologies — ranging from swing trading and day trading to longer-term momentum and trend-following strategies — each backed by transparent performance metrics and historical track records. For investors monitoring WAT's evolving post-acquisition story, the Trending AI Robots section provides a practical lens through which to identify algorithmic strategies aligned with current market conditions.
2026 Outlook and What Investors Should Watch
The immediate catalyst for Waters shares is the Q2 2026 earnings report on August 4, 2026. Management guided for Q2 adjusted EPS of $2.95 to $3.05 on total revenue of $1.616 billion to $1.631 billion. Analysts will closely scrutinize several metrics: organic constant-currency growth in the legacy Analytical Sciences division, sequential progress in the acquired Biosciences and Advanced Diagnostics units, gross margin trajectory, and the pace of synergy realization. Management's 180-day growth revitalization plan for the acquired businesses — including pricing discipline enhancements, contract compliance improvements, and plans to localize flow cytometry manufacturing in China beginning Q3 2026 — will be a focal point.
Macroeconomic considerations also warrant attention. China represents approximately 13% of Waters' revenue, and ongoing geopolitical tensions and DRG-related headwinds have created uneven demand patterns in the region. Currency fluctuations remain a modest headwind, and respiratory testing seasonality could affect the Diagnostics division. On the regulatory front, additional FDA clearances for the combined product portfolio could serve as positive catalysts through year-end. The instrument replacement cycle, GLP-1 manufacturing demand, PFAS testing applications, and growth in biologics characterization all represent structural tailwinds that underpin the raised full-year guidance and analyst optimism.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for WAT turns positive, indicating new upward trend
WAT saw its Momentum Indicator move above the 0 level on July 28, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned positive. In of the 87 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for WAT just turned positive on August 04, 2026. Looking at past instances where WAT's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .
WAT moved above its 50-day moving average on July 21, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where WAT advanced for three days, in of 277 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where WAT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
WAT broke above its upper Bollinger Band on August 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. WAT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.674) is normal, around the industry mean (69.022). P/E Ratio (104.686) is within average values for comparable stocks, (150.346). Projected Growth (PEG Ratio) (1.805) is also within normal values, averaging (1.672). WAT has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.007). P/S Ratio (6.667) is also within normal values, averaging (8.434).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WAT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of analytical technologies: liquid chromatography, mass spectrometry, and thermal analysis
Industry MedicalSpecialties